FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:540-546 August 22, 1996 Number 8 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background To avert major hemorrhage, physicians need to know the lowest intensity of anticoagulation that is effective in preventing stroke in patients with atrial fibrillation. Since the low rate of stroke has made it difficult to perform prospective studies to resolve this issue, we conducted a case–control study.

Methods We studied 74 consecutive patients with atrial fibrillation who were admitted to our hospital from 1989 through 1994 after having an ischemic stroke while taking warfarin. For each patient with stroke, three controls with nonrheumatic atrial fibrillation who were treated as outpatients were randomly selected from the 1994 registry of the anticoagulant-therapy unit (222 controls). We used the international normalized ratio (INR) to measure the intensity of anticoagulation. For the patients with stroke, we used the INR at admission; for the controls, we selected the INR that was measured closest to the month and day of the matched case patient's hospital admission.

Results The risk of stroke rose steeply at INRs below 2.0. At an INR of 1.7, the adjusted odds ratio for stroke, as compared with the risk at an INR of 2.0, was 2.0 (95 percent confidence interval, 1.6 to 2.4); at an INR of 1.5, it was 3.3 (95 percent confidence interval, 2.4 to 4.6); and at an INR of 1.3, it was 6.0 (95 percent confidence interval, 3.6 to 9.8). Other independent risk factors were previous stroke (odds ratio, 10.4; 95 percent confidence interval, 4.4 to 24.5), diabetes mellitus (odds ratio, 2.9; 95 percent confidence interval, 1.3 to 6.5), hypertension (odds ratio, 2.5; 95 percent confidence interval, 1.1 to 5.7), and current smoking (odds ratio, 5.7; 95 percent confidence interval, 1.4 to 24.0).

Conclusions Among patients with atrial fibrillation, anticoagulant prophylaxis is effective at INRs of 2.0 or greater. Since previous studies have indicated that the risk of hemorrhage rises rapidly at INRs greater than 4.0 to 5.0, tight control of anticoagulant therapy to maintain the INR between 2.0 and 3.0 is a better strategy than targeting lower, less effective levels of anticoagulation.

Source Information

From the General Internal Medicine Division, Clinical Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston.

Address reprint requests to Dr. Hylek at the Medical Practices Evaluation Center, S 50-9, Massachusetts General Hospital, Boston, MA 02114.

Full Text of this Article

Related Letters:

Anticoagulation for Nonrheumatic Atrial Fibrillation
Hart R. G., Hylek E. M., Skates S. A., Singer D. E.
Extract | Full Text  
N Engl J Med 1997; 336:441-442, Feb 6, 1997. Correspondence

This article has been cited by other articles:

• 2006 WRITING COMMITTEE MEMBERS, , Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C. Jr, Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., O'Rourke, R. A., Otto, C. M., Shah, P. M., Shanewise, J. S. (2008). 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 118: e523-e661 [Full Text]  
• Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C. Jr, Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., O'Rourke, R. A., Otto, C. M., Shah, P. M., Shanewise, J. S., Nishimura, R. A., Carabello, B. A., Faxon, D. P., Freed, M. D., Lytle, B. W., O'Gara, P. T., O'Rourke, R. A., Shah, P. M. (2008). 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52: e1-e142 [Full Text]  
• Romero, J. R., Morris, J., Pikula, A. (2008). Review: Stroke prevention: modifying risk factors. Therapeutic Advances in Cardiovascular Disease 2: 287-303 [Abstract]  
• Garcia, D. A, Witt, D. M, Hylek, E., Wittkowsky, A. K, Nutescu, E. A, Jacobson, A., Moll, S., Merli, G. J, Crowther, M., Earl, L., Becker, R. C, Oertel, L., Jaffer, A., Ansell, J. E (2008). Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum. The Annals of Pharmacotherapy 42: 979-988 [Abstract] [Full Text]  
• Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., Palareti, G. (2008). Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 160S-198S [Abstract] [Full Text]  
• Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., Ansell, J. (2008). The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 299S-339S [Abstract] [Full Text]  
• Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., Manning, W. J. (2008). Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 546S-592S [Abstract] [Full Text]  
• Garwood, C. L, Corbett, T. L (2008). Use of Anticoagulation in Elderly Patients with Atrial Fibrillation Who Are at Risk for Falls. The Annals of Pharmacotherapy 42: 523-532 [Abstract] [Full Text]  
• Weir, N U (2008). An update on cardioembolic stroke. Postgrad. Med. J. 84: 133-142 [Abstract] [Full Text]  
• Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K.-H., Lip, G. Y.H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., Vincent, A., Breithardt, G. (2007). Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28: 2803-2817 [Abstract] [Full Text]  
• Nutescu, E. A. (2007). ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation. Am J Health Syst Pharm 64: 2281-2291 [Full Text]  
• Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K.-H., Lip, G. Y.H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., Vincent, A., Breithardt, G. (2007). Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 9: 1006-1023 [Abstract] [Full Text]  
• Connolly, S. J., Eikelboom, J., O'Donnell, M., Pogue, J., Yusuf, S. (2007). Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. Circulation 116: 449-455 [Full Text]  
• Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society . J Am Coll Cardiol 48: 854-906 [Full Text]  
• Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA TASK FORCE MEMBERS, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC COMMITTEE FOR PRACTICE GUIDELINES, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: 700-752 [Full Text]  
• Authors/Task Force Members, , Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L., ACC/AHA (Practice Guidelines) Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 27: 1979-2030 [Full Text]  
• Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C. Jr, Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., O'Rourke, R. A., Otto, C. M., Shah, P. M., Shanewise, J. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B. (2006). ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48: e1-e148 [Full Text]  
• Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., Johnston, S. C., Katzan, I., Kelly-Hayes, M., Kenton, E. J., Marks, M., Schwamm, L. H., Tomsick, T. (2006). Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.. Circulation 113: e409-e449 [Abstract] [Full Text]  
• Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., Johnston, S. C., Katzan, I., Kelly-Hayes, M., Kenton, E. J., Marks, M., Schwamm, L. H., Tomsick, T. (2006). Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.. Stroke 37: 577-617 [Abstract] [Full Text]  
• McGriff-Lee, N. J, Csako, G., Chen, J. T, Dang, D. K, Rosenfeld, K. G, Cannon, R. O, Macklin, L R., Wesley, R. A, Anticoagulation Working Group, (2005). Search for Predictors of Nontherapeutic INR Results with Warfarin Therapy. The Annals of Pharmacotherapy 39: 1996-2002 [Abstract] [Full Text]  
• Capucci, A., Santini, M., Padeletti, L., Gulizia, M., Botto, G., Boriani, G., Ricci, R., Favale, S., Zolezzi, F., Di Belardino, N., Molon, G., Drago, F., Villani, G. Q., Mazzini, E., Vimercati, M., Grammatico, A., on behalf of the Italian AT500 Registry Investigat, (2005). Monitored Atrial Fibrillation Duration Predicts Arterial Embolic Events in Patients Suffering From Bradycardia and Atrial Fibrillation Implanted With Antitachycardia Pacemakers. J Am Coll Cardiol 46: 1913-1920 [Abstract] [Full Text]  
• Voller, H. (2005). In defence of current treatment options: where are we now?. Eur Heart J Suppl 7: E4-E9 [Full Text]  
• Murphy, R. (2005). Maximizing current treatment options: exploring psychological barriers to change. Eur Heart J Suppl 7: E10-E14 [Full Text]  
• Katira, R, Chauhan, A, More, R S (2005). Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. Postgrad. Med. J. 81: 370-375 [Abstract] [Full Text]  
• O'Donnell, M., Agnelli, G., Weitz, J. I. (2005). Emerging therapies for stroke prevention in atrial fibrillation. Eur Heart J Suppl 7: C19-C27 [Abstract] [Full Text]  
• Emmerich, J., Le Heuzey, J.-Y., Bath, P. M.W., Connolly, S. J. (2005). Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. Eur Heart J Suppl 7: C28-C33 [Abstract] [Full Text]  
• Fang, M. C., Singer, D. E. (2005). Warfarin or Not Warfarin?. ANN INTERN MED 142: 676-676 [Full Text]  
• Scholten, M. F., Thornton, A. S., Mekel, J. M., Koudstaal, P. J., Jordaens, L. J. (2005). Anticoagulation in atrial fibrillation and flutter. Europace 7: 492-499 [Abstract] [Full Text]  
• Page, R. L. (2004). Newly Diagnosed Atrial Fibrillation. NEJM 351: 2408-2416 [Full Text]  
• Reynolds, M. W., Fahrbach, K., Hauch, O., Wygant, G., Estok, R., Cella, C., Nalysnyk, L. (2004). Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation: A Systematic Review and Metaanalysis. Chest 126: 1938-1945 [Abstract] [Full Text]  
• Hauch, O., Bullano, M. F., Sarawate, C., Iarocci, T., Willey, V. J., Spyropoulos, A. C. (2004). International Normalized Ratio (INR) Monitoring in Patients with Recurrent Venous Thromboembolism (VTE): Opportunity for Improvement in Quality of Management?.. ASH ANNUAL MEETING ABSTRACTS 104: 2202-2202 [Abstract] [Full Text]  
• Fang, M. C., Chang, Y., Hylek, E. M., Rosand, J., Greenberg, S. M., Go, A. S., Singer, D. E. (2004). Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation. ANN INTERN MED 141: 745-752 [Abstract] [Full Text]  
• Perez-Gomez, F., Alegria, E., Berjon, J., Iriarte, J. A., Zumalde, J., Salvador, A., Mataix, L., NASPEAF Investigators, (2004). Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study. J Am Coll Cardiol 44: 1557-1566 [Abstract] [Full Text]  
• Falk, R. H. (2004). Reconsidering combined antiplatelet and anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol 44: 1567-1569 [Full Text]  
• Gage, B. F., van Walraven, C., Pearce, L., Hart, R. G., Koudstaal, P. J., Boode, B.S.P., Petersen, P. (2004). Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin. Circulation 110: 2287-2292 [Abstract] [Full Text]  
• Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., Hylek, E. (2004). The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 204S-233S [Abstract] [Full Text]  
• Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S. (2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 287S-310S [Abstract] [Full Text]  
• Singer, D. E., Albers, G. W., Dalen, J. E., Go, A. S., Halperin, J. L., Manning, W. J. (2004). Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 429S-456S [Abstract] [Full Text]  
• Hanna, I. R., Kolm, P., Martin, R., Reisman, M., Gray, W., Block, P. C. (2004). Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): Six-month echocardiographic follow-up. J Am Coll Cardiol 43: 1868-1872 [Abstract] [Full Text]  
• Bode, C. (2004). Recent trials in atrial fibrillation: lessons learned beyond rate and rhythm. Eur Heart J Suppl 6: B15-B19 [Abstract] [Full Text]  
• Olsson, S.B. (2004). New advances in stroke prevention in atrial fibrillation: ximelagatran and direct thrombin inhibition. Eur Heart J Suppl 6: B20-B24 [Abstract] [Full Text]  
• O'Donnell, M., Hirsh, J. (2004). Establishing an Optimal Therapeutic Range for Coumarins: Filling in the Gaps. Arch Intern Med 164: 588-590 [Full Text]  
• Boos, C.J., Carlsson, J., More, R.S. (2003). Rate or rhythm control in persistent atrial fibrillation?. QJM 96: 881-892 [Abstract] [Full Text]  
• Go, A. S., Hylek, E. M., Chang, Y., Phillips, K. A., Henault, L. E., Capra, A. M., Jensvold, N. G., Selby, J. V., Singer, D. E. (2003). Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice?. JAMA 290: 2685-2692 [Abstract] [Full Text]  
• Gadisseur, A. P. A., Breukink-Engbers, W. G. M., van der Meer, F. J. M., van den Besselaar, A. M. H., Sturk, A., Rosendaal, F. R. (2003). Comparison of the Quality of Oral Anticoagulant Therapy Through Patient Self-management and Management by Specialized Anticoagulation Clinics in the Netherlands: A Randomized Clinical Trial. Arch Intern Med 163: 2639-2646 [Abstract] [Full Text]  
• Singer, D. E. (2003). A 60-Year-Old Woman With Atrial Fibrillation. JAMA 290: 2182-2189 [Full Text]  
• Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., Singer, D. E. (2003). Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. NEJM 349: 1019-1026 [Abstract] [Full Text]  
• Waldo, A. L. (2003). Stroke Prevention in Atrial Fibrillation. JAMA 290: 1093-1095 [Full Text]  
• Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 41: 1633-1652 [Full Text]  
• Hirsh, J., Fuster, V., Ansell, J., Halperin, J. L. (2003). American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation 107: 1692-1711 [Full Text]  
• Kuhlkamp, V., Seipel, L., Healy, E. C., Bhaskarabhatla, K., Manning, W. J., Wyse, D. G., Van Gelder, I. C., Crijns, H. J.G.M. (2003). Atrial Fibrillation -- Rate versus Rhythm Control. NEJM 348: 1284-1286 [Full Text]  
• Gallagher, M. M., Hennessy, B. J., Edvardsson, N., Hart, C. M., Shannon, M. S., Obel, O. A., Al-Saady, N. M., Camm, A. J. (2002). Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 40: 926-933 [Abstract] [Full Text]  
• Iyigun, I., Stollberger, C., Wehinger, C., Finsterer, J. (2002). Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial Fibrillation * Response. Stroke 33: 2150-2152 [Full Text]  
• Hankey, G. J. (2002). Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial: Is Warfarin Really a Reasonable Therapeutic Alternative to Aspirin for Preventing Recurrent Noncardioembolic Ischemic Stroke?. Stroke 33: 1723-1726 [Full Text]  
• McCormick, D., Gurwitz, J. H., Goldberg, R. J., Becker, R., Tate, J. P., Elwell, A., Radford, M. J. (2001). Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting. Arch Intern Med 161: 2458-2463 [Abstract] [Full Text]  
• Fuster, V., Ryden, L. E., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Levy, S., McNamara, R. L., Prystowsky, E. N., Wann, L. S., Wyse, D. G., Gibbons, R. J., Antman, E. M., Alpert, J. S., Faxon, D. P., Fuster, V., Gregoratos, G., Hiratzka, L. F., Jacobs, A. K., Russell, R. O., Smith, S. C. Jr., Klein, W. W., Alonso-Garcia, A., Blomstrom-Lundqvist, C., de Backer, G., Flather, M., Hradec, J., Oto, A., Parkhomenko, A., Silber, S., Torbicki, A. (2001). ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 104: 2118-2150 [Full Text]  
• Knight, E. L., Avorn, J. (2001). Quality Indicators for Appropriate Medication Use in Vulnerable Elders. ANN INTERN MED 135: 703-710 [Full Text]  
• (2001). Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 22: 1852-1923  
• Fuster, V., Ryden, L. E., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Levy, S., McNamara, R. L., Prystowsky, E. N., Wann, L. S., Wyse, D. G., Gibbons, R. J., Antman, E. M., Alpert, J. S., Faxon, D. P., Fuster, V., Gregoratos, G., Hiratzka, L. F., Jacobs, A. K., Russell, R. O., Smith, S. C. Jr, Klein, W. W., Alonso-Garcia, A., Blomstrom-Lundqvist, C., De Backer, G., Flather, M., Hradec, J., Oto, A., Parkhomenko, A., Silber, S., Torbicki, A. (2001). ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 38: 1231-1265 [Full Text]  
• Fuster, V., Ryden, L. E., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Levy, S., McNamara, R. L., Prystowsky, E. N., Wann, L. S., Wyse, D. G., Gibbons, R. J., Antman, E. M., Alpert, J. S., Faxon, D. P., Fuster, V., Gregoratos, G., Hiratzka, L. F., Jacobs, A. K., Russell, R. O., Smith, S. C. Jr, Klein, W. W., Alonso-Garcia, A., Blomstrom-Lundqvist, C., De Backer, G., Flather, M., Hradec, J., Oto, A., Parkhomenko, A., Silber, S., Torbicki, A. (2001). ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 38: 1266-1266 [Full Text]  
• Falk, R. H. (2001). Atrial Fibrillation. NEJM 344: 1067-1078 [Full Text]  
• Hart, R. G., Halperin, J. L. (2001). Atrial Fibrillation and Stroke : Concepts and Controversies. Stroke 32: 803-808 [Full Text]  
• Ginsberg, J. A., Crowther, M. A., White, R. H., Ortel, T. L. (2001). Anticoagulation Therapy. ASH Education Book 2001: 339-357 [Abstract] [Full Text]  
• Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., Deykin, D. (2001). Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range. Chest 119: 8S-21S [Full Text]  
• Ansell, J., Hirsh, J., Dalen, J., Bussey, H., Anderson, D., Poller, L., Jacobson, A., Deykin, D., Matchar, D. (2001). Managing Oral Anticoagulant Therapy. Chest 119: 22S-38S [Full Text]  
• Levine, M. N., Raskob, G., Landefeld, S., Kearon, C. (2001). Hemorrhagic Complications of Anticoagulant Treatment. Chest 119: 108S-121S [Full Text]  
• Albers, G. W., Dalen, J. E., Laupacis, A., Manning, W. J., Petersen, P., Singer, D. E. (2001). Antithrombotic Therapy in Atrial Fibrillation. Chest 119: 194S-206S [Full Text]  
• Thijssen, H. H., Flinois, J.-P., Beaune, P. H. (2000). Cytochrome P4502C9 Is the Principal Catalyst of Racemic Acenocoumarol Hydroxylation Reactions in Human Liver Microsomes. Drug Metab. Dispos. 28: 1284-1290 [Abstract] [Full Text]  
• MacCallum, P. K., Brennan, P. J., Meade, T. W., for the Medical Research Council's General Practic, (2000). Minimum Effective Intensity of Oral Anticoagulant Therapy in Primary Prevention of Coronary Heart Disease. Arch Intern Med 160: 2462-2468 [Abstract] [Full Text]  
• Ansell, J. E. (2000). The Quality of Anticoagulation Management. Arch Intern Med 160: 895-896 [Full Text]  
• Yamaguchi, T. (2000). Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation : A Multicenter, Prospective, Randomized Trial. Stroke 31: 817-821 [Abstract] [Full Text]  
• Hart, R. G., Pearce, L. A., Rothbart, R. M., McAnulty, J. H., Asinger, R. W., Halperin, J. L., for the Stroke Prevention in Atrial Fibrillation I, (2000). Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol 35: 183-187 [Abstract] [Full Text]  
• Ansell, J. E., Weitz, J. I., Comerota, A. J. (2000). Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. ASH Education Book 2000: 266-284 [Abstract] [Full Text]  
• Lip, G.Y.H. (1999). Assessment of risk of thromboembolism in atrial fibrillation: which patients should be anticoagulated?. Eur Heart J 20: 1757-1758  
• Hart, R. G., Halperin, J. L. (1999). Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention. ANN INTERN MED 131: 688-695 [Abstract] [Full Text]  
• Wallis, D. E., Quintos, R., Wehrmacher, W., Messmore, H. (1999). Safety of Warfarin Anticoagulation in Patients With Heparin-Induced Thrombocytopenia. Chest 116: 1333-1338 [Abstract] [Full Text]  
• HART, R. G (1999). Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young. Heart 82: 539-540 [Full Text]  
• Albers, G. W., Hart, R. G., Lutsep, H. L., Newell, D. W., Sacco, R. L. (1999). Supplement to the Guidelines for the Management of Transient Ischemic Attacks : A Statement From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 30: 2502-2511 [Full Text]  
• Hart, R. G., Benavente, O., McBride, R., Pearce, L. A. (1999). Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. ANN INTERN MED 131: 492-501 [Abstract] [Full Text]  
• Eagle, K. A., Guyton, R. A., Davidoff, R., Ewy, G. A., Fonger, J., Gardner, T. J., Gott, J. P., Herrmann, H. C., Marlow, R. A., Nugent, W. C., O'Connor, G. T., Orszulak, T. A., Rieselbach, R. E., Winters, W. L., Yusuf, S., Gibbons, R. J., Alpert, J. S., Eagle, K. A., Gardner, T. J., Garson, A. Jr., Gregoratos, G., Russell, R. O., Smith, S. C. Jr. (1999). ACC/AHA guidelines for coronary artery bypass graft surgery: A report of the American College of Cardiology/ American Heart Association task force on Practice Guidelines (Committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 34: 1262-1347 [Full Text]  
• Gullov, A. L., Koefoed, B. G., Petersen, P. (1999). Bleeding During Warfarin and Aspirin Therapy in Patients With Atrial Fibrillation: The AFASAK 2 Study. Arch Intern Med 159: 1322-1328 [Abstract] [Full Text]  
• Hart, R. G., Pearce, L. A., McBride, R., Rothbart, R. M., Asinger, R. W. (1999). Factors Associated With Ischemic Stroke During Aspirin Therapy in Atrial Fibrillation : Analysis of 2012 Participants in the SPAF I–III Clinical Trials. Stroke 30: 1223-1229 [Abstract] [Full Text]  
• Ezekowitz, M. D., Levine, J. A. (1999). Preventing Stroke in Patients With Atrial Fibrillation. JAMA 281: 1830-1835 [Abstract] [Full Text]  
• Ezekowitz, M. D., James, K. E., Radford, M. J., Rickles, F. R., Redmond, N. (1999). Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring. J CARDIOVASC PHARMACOL THER 4: 3-8 [Abstract]  
• Albers, G. W. (1998). Choice of Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation: Warfarin, Aspirin, or Both?. Arch Intern Med 158: 1487-1491 [Full Text]  
• Gullov, A. L., Koefoed, B. G., Petersen, P., Pedersen, T. S., Andersen, E. D., Godtfredsen, J., Boysen, G. (1998). Fixed Minidose Warfarin and Aspirin Alone and in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 158: 1513-1521 [Abstract] [Full Text]  
• Gage, B. F., Cardinalli, A. B., Owens, D. K. (1998). Cost-Effectiveness of Preference-Based Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation. Stroke 29: 1083-1091 [Abstract] [Full Text]  
• Koudstaal, P. J., Koudstaal, A. (1998). Stroke Prevention in Patients With Atrial Fibrillation: What Have We Learned?. J CARDIOVASC PHARMACOL THER 3: 85-89  
• Li, Y.-G., Hohnloser, S. H. (1998). Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?. J CARDIOVASC PHARMACOL THER 3: 185-194 [Abstract]  
• Brass, L. M., Krumholz, H. M., Scinto, J. M., Radford, M. (1997). Warfarin Use Among Patients With Atrial Fibrillation. Stroke 28: 2382-2389 [Abstract] [Full Text]  
• Feinberg, W. M., Cornell, E. S., Nightingale, S. D., Pearce, L. A., Tracy, R. P., Hart, R. G., Bovill, E. G. (1997). Relationship Between Prothrombin Activation Fragment F1.2 and International Normalized Ratio in Patients With Atrial Fibrillation. Stroke 28: 1101-1106 [Abstract] [Full Text]  
• Hart, R. G., Hylek, E. M., Skates, S. A., Singer, D. E. (1997). Anticoagulation for Nonrheumatic Atrial Fibrillation. NEJM 336: 441-442 [Full Text]  
• (1996). Lowest Effective INR for Atrial Fibrillation. Journal Watch Cardiology 1996: 12-12 [Full Text]  
• (1996). INTENSITY OF ANTICOAGULATION FOR ATRIAL FIBRILLATION. JWatch General 1996: 4-4 [Full Text]  
• Rosendaal, F.R. (1996). The Scylla and Charybdis of Oral Anticoagulant Treatment. NEJM 335: 587-589 [Full Text]